Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Luca Cantarini; Giuseppe Lopalco; Antonio Vitale; Francesco Caso; Giovanni Lapadula; Florenzo Iannone; Mauro Galeazzi; Donato Rigante

doi:10.1111/1756-185X.12521

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Luca Cantarini
, Giuseppe Lopalco
, Antonio Vitale
, Francesco Caso
, Giovanni Lapadula
, Florenzo Iannone
, Mauro Galeazzi
, Donato Rigante

Risultato della ricerca: Contributo in rivista › Articolo › peer review

6 Citazioni (Scopus)

Abstract

The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.

Lingua originale	Inglese
pagine (da-a)	473-475
Numero di pagine	3
Rivista	International Journal of Rheumatic Diseases
Volume	18
DOI	https://doi.org/10.1111/1756-185X.12521
Stato di pubblicazione	Pubblicato - 2015

Keywords

Autoinflammation

Accesso al documento

10.1111/1756-185X.12521

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Cantarini, L., Lopalco, G., Vitale, A., Caso, F., Lapadula, G., Iannone, F., Galeazzi, M., & Rigante, D. (2015). Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. International Journal of Rheumatic Diseases, 18, 473-475. https://doi.org/10.1111/1756-185X.12521

@article{870234ea948244298cd9d65d03314cb9,

title = "Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant",

abstract = "The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.",

keywords = "Autoinflammation, Autoinflammation",

author = "Luca Cantarini and Giuseppe Lopalco and Antonio Vitale and Francesco Caso and Giovanni Lapadula and Florenzo Iannone and Mauro Galeazzi and Donato Rigante",

year = "2015",

doi = "10.1111/1756-185X.12521",

language = "English",

volume = "18",

pages = "473--475",

journal = "International Journal of Rheumatic Diseases",

issn = "1756-185X",

publisher = "John Wiley and Sons Inc.",

}

Cantarini, L, Lopalco, G, Vitale, A, Caso, F, Lapadula, G, Iannone, F, Galeazzi, M & Rigante, D 2015, 'Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant', International Journal of Rheumatic Diseases, vol. 18, pagg. 473-475. https://doi.org/10.1111/1756-185X.12521

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. / Cantarini, Luca; Lopalco, Giuseppe; Vitale, Antonio et al.
In: International Journal of Rheumatic Diseases, Vol. 18, 2015, pag. 473-475.

Risultato della ricerca: Contributo in rivista › Articolo › peer review

TY - JOUR

T1 - Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

AU - Cantarini, Luca

AU - Lopalco, Giuseppe

AU - Vitale, Antonio

AU - Caso, Francesco

AU - Lapadula, Giovanni

AU - Iannone, Florenzo

AU - Galeazzi, Mauro

AU - Rigante, Donato

PY - 2015

Y1 - 2015

N2 - The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.

AB - The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.

KW - Autoinflammation

UR - http://hdl.handle.net/10807/68774

U2 - 10.1111/1756-185X.12521

DO - 10.1111/1756-185X.12521

M3 - Article

SN - 1756-185X

VL - 18

SP - 473

EP - 475

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

ER -

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo